Salute ed economia

Vaccini anti Covid 19 e sussulti della Borsa

La ricerca scientifica sui vaccini necessari per arginare la diffusione della pandemia e i notevoli ritorni finanziari attesi dagli azionisti delle grandi società farmaceutiche

Nurse Kathe Olmstead, right, gives volunteer Melissa Harting, of Harpersville, N.Y. an injection as the world's biggest study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc.,  gets underway Monday, July 27, 2020, in Binghamton, N.Y. (AP Photo/Hans Pennink)
University of Miami Miller School of Medicine lab tech Sendy Puerto processes blood samples in the specimen processing lab from study participants, Wednesday, Sept. 2, 2020, in Miami. The volunteers are taking part in testing the NIH-funded Moderna COVID-19 vaccine. Miami is one of 89 cities around the U.S. that's testing the Moderna COVID-19 vaccine. (AP Photo/Taimy Alvarez)
Infectious diseases research assistant Irma Barreto Ojeda, right, holds a tray with a syringe containing either a placebo or the Moderna COVID-19 vaccine as she confers with University of Miami Miller School of Medicine nurse Inza Patton, left, and pharmacist Barbara Huang Wednesday, Sept. 2, 2020 in Miami, as part of the National Institutes of Health-funded third phase of a clinical trial. They go through a verification process to confirm the right study participant is receiving the correct injection of either a placebo or the vaccine, which is only known to the pharmacy team. (AP Photo/Taimy Alvarez)
University of Miami Miller School of Medicine lab tech Sendy Puerto processes blood samples in the specimen processing lab from study participants, Wednesday, Sept. 2, 2020, in Miami. The volunteers are taking part in testing the NIH funded Moderna COVID-19 vaccine. Miami is one of 89 cities around the U.S. that's testing the Moderna COVID-19 vaccine. (AP Photo/Taimy Alvarez)
Empty collection vials are stored for the NIH funded Moderna COVID-19 vaccine third phase clinical trail wait to be processed in the specimen processing lab at the University of Miami Miller School of Medicine in Miami, Fla., Wednesday, Sept. 2, 2020 in Miami. (AP Photo/Taimy Alvarez)
-University of Miami Miller School of Medicine lab tech Sendy Puerto processes blood sample in the specimen processing lab from study participants who volunteered to take part in testing the NIH funded Moderna COVID-19 vaccine in Miami, Florida Wednesday, September 2, 2020. Miami is one of 89 cities around the U.S. taking part in the NIH funded biotech company, Moderna, study testing a Covid-19 vaccine in humans as part of the third phase of a clinical trial. (AP Photo/Taimy Alvarez)
A man wearing a mask passes the New York Stock Exchange, Monday, Nov. 16, 2020, in New York. Stock markets are rallying on news that a second coronavirus vaccine shows promise. (AP Photo/Mark Lennihan)
People walk by the New York Stock Exchange, Monday, Nov. 16, 2020, in New York. Stock markets are rallying on news that a second coronavirus vaccine shows promise. (AP Photo/Mark Lennihan)
FILE - This March 16, 2020, file photo shows vials used by pharmacists to prepare syringes used on the first day of a first-stage safety study of the potential vaccine for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle. Moderna said Monday, Nov. 16, its COVID-19 vaccine is proving to be highly effective in a major trial. (AP Photo/Ted S. Warren, File)
FILE - This Wednesday, Sept, 2, 2020, file photo shows University of Miami Miller School of Medicine lab tech Sendy Puerto processing blood samples in the specimen processing lab from study participants who volunteered to take part in testing the National Institutes of Health-funded Moderna COVID-19 vaccine in Miami. Sen. Rob Portman, R-Ohio, is participating in a COVID-19 vaccine study, hoping to encourage others to volunteer to take part in testing. (AP Photo/Taimy Alvarez, File)
A street sign is displayed at the New York Stock Exchange in New York, Monday, Nov. 23, 2020.  Wall Street busted through its latest milestone Tuesday, when the Dow Jones Industrial Average topped 30,000 for the first time. It’s an attention-grabbing psychological threshold, and it’s an encouraging signal that the market’s rally is broadening beyond the handful of tech stocks that carried Wall Street through the pandemic.  (AP Photo/Seth Wenig)
FILE - AP Photo/Taimy Alvarez
Currency traders watch monitors at the foreign exchange dealing room of the KEB Hana Bank headquarters in Seoul, South Korea, Monday, Nov. 30, 2020. Asian shares were mixed on Monday on renewed caution despite a record high finish on Wall Street last week driven by hopes for a COVID-19 vaccine and relief for the global economy. (AP Photo/Ahn Young-joon)
FILE - In this July 27, 2020, file photo, nurse Kathe Olmstead prepares a shot that is part of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, N.Y. Moderna Inc. says it will ask U.S. and European regulators to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection. (AP Photo/Hans Pennink, File)
FILE - In this Monday, May 18, 2020, file photo, a sign marks an entrance to a Moderna, Inc., building, in Cambridge, Mass. Moderna Inc. says it will ask U.S. and European regulators to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection. (AP Photo/Bill Sikes, File)

Dobbiamo abituarci alle notizie che annunciano successi e fallimenti relativi ai vaccini in preparazione per combattere la diffusione su scala mondiale del Covid 19.

Il conseguente andamento dei titoli azionari delle grandi società impegnate nella ricerca farmaceutiche rappresenta la conferma delle aspettative sui notevoli guadagni attesi dagli azionisti in un sistema che non concepisce la possibilità di non concedere alle imprese private la licenza esclusiva di produzione e commercializzazione del vaccino.  E questo nonostante le ingenti risorse pubbliche investite nel campo della ricerca, che dovrebbero orientare la produzione verso l’accesso universale e gratuito ai vaccini come garanzia efficace di salute globale.

La società statunitense Moderna, fondata nel 2010 con sede a Cambridge nel Massachusetts, ha visto lo straordinario aumento del 17% del valore delle sue azione nel mercato borsistico elettronico del Nasdaq dopo aver annunciato di aver richiesto, negli Usa e in Europa, l’autorizzazione d’emergenza alla distribuzione del suo vaccino contro il Covid 19.

La Moderna vede tra i suoi fondatori tre insigni scienziati (Timothy A. Springer , Kenneth R. Chien, Robert Samuel Langer,)  assieme a 2 esperti di finanza  (Noubar Afeyan e  Flagship Pioneering ).

Il loro vaccino dimostrerebbe alti livelli di efficacia oltre al vantaggio di non presentare i problemi logistici di conservazione come quello della rivale Pfizer che richiede il trasporto in sicurezza a 80 gradi sottozero. La Pfizer, anch’essa statunitense, è considerata la più grande società del settore ed è quotata alla borsa di New York.

Guarda anche

Edicola Digitale Città Nuova - Reader Scarica l'app
Simple Share Buttons